Highlights of Ophthalmology

Register      Login

SEARCH WITHIN CONTENT

FIND ARTICLE

Volume / Issue

Online First

Related articles

VOLUME 49 , ISSUE 6ENG ( December, 2021 ) > List of Articles

Povidone-iodine in Ophthalmology: Background and Update

Rahul Rachwani Anil, Carlos Rocha de Lossada

Keywords : Povidone-iodine, iodine, endophthalmitis, cataracts, anti-VEGF

Citation Information : Anil RR, de Lossada CR. Povidone-iodine in Ophthalmology: Background and Update. 2021; 49 (6ENG):23-33.

DOI: 10.5005/hoe-10101-49603

Published Online: 15-12-2021

Copyright Statement:  Copyright © 2021; Jaypee Brothers Medical Publishers (P) Ltd.


Abstract

Historically, iodine in its iodized stain form has been used for more than a century as an antiseptic. However, despite its effectiveness, its use has been largely compromised by its numerous side effects, such as burning, irritation and allergies. Guidelines on the use of povidone-iodine (PVI) in evidence-based ophthalmology place this solution at a concentration of 5-10% as the gold standard in the prophylaxis of endophthalmitis prior to cataract surgery and intravitreal injections. The purpose of this review is to present the current evidence on the use of PVI in ophthalmology, in addition to its indications not yet approved at concentrations below 5%.


PDF Share
  1. Garner JS, Favero MS. CDC guidelines for the prevention and control of nosocomial infections. Guideline for handwashing and hospital environmental control, 1985. Supersedes guideline for hospital environmental control published in 1981. Am J Infect Control 1986; 14:110–129.
  2. Grzybowski A, Brona P. Povidone-iodine is still a premium antiseptic measure ocular surgery. Acta Ophthalmol [Internet] 2017; 95:e253–e254; Available from: http://dx.doi.org/10.1111/aos.13144.
  3. Gottardi W. Iodine and iodine compounds. In: Block SS, ed. Disinfection, Sterilization, and Preservation. Philadelphia, London: Lea & Febinger; 1991. pp. 152–166.
  4. Grzybowski A, Kanclerz P, Myers WG. The use of povidone-iodine in ophthalmology. Curr Opin Ophthalmol. 2018 Jan;29(1):19-32. doi: 10.1097/ICU.0000000000000437. PMID: 28984794.
  5. Zamora JL. Chemical and microbiologic characteristics and toxicity of povidone-iodine solutions. Am J Surg 1986; 151: 400–406.
  6. Benevento WJ, Murray P, Reed CA, et al. The sensitivity of Neisseria gonorrhoeae, Chlamydia trachomatis, and herpes simplex type II to disinfection with povidone-iodine. Am J Ophthalmol 1990; 109: 329–333.
  7. Edington M, Ramaesh K, Lockington D. Virucidal benefits of povidone-iodine use on the ocular surface: a review. BMJ Open Ophthalmology 2020;5:e000509. doi:10.1136/bmjophth-2020-000509
  8. Shelanski HA, Shelanski MV. PVP-iodine: history, toxicity and therapeutic uses. J Int Coll Surg 1956; 25:727–734.
  9. Shimada H, Nakashizuka H, Grzybowski A. Prevention and treatment of postoperative endophthalmitis using povidone-iodine. Curr Pharm Des. 2017; 23:574–585.
  10. Sriwilaijaroen N, Wilairat P, Hiramatsu H, et al. Mechanisms of the action of povidone-iodine against human and avian influenza A viruses: its effects on hemagglutination and sialidase activities. Virol J 2009;6:124.
  11. Bigliardi PL, Alsagoff SAL, El-Kafrawi HY, et al. Povidone iodine in wound healing: a review of current concepts and practices. Int J Surg 2017;44:260–8.
  12. Eggers M. Infectious disease management and control with povidone iodine. Infect Dis Ther 2019;8:581–93.
  13. Schreier H, Erdos G, Reimer K, et al. Molecular effects of povidone-iodine on relevant microorganisms: an electron-microscopic and biochemical study. Dermatology 1997;195(Suppl 2):111–6.
  14. Barry P, Cordoves L, Susanne G. ESCRS Guidelines for Prevention and Treatment of Endophthalmitis Following Cataract Surgery: Data Dilemmas and Conclusions 2013 [Internet] 2013; Available from: http://escrs.org/endophthalmitis/guidelines/ENGLISH.pdf.
  15. Wykoff CC, Parrott MB, Flynn HW Jr, et al. Nosocomial acute-onset postoperative endophthalmitis at a university teaching hospital. Am J Ophthalmol 2010; 150:392–8e2.
  16. Shimada H, Nakashizuka H, Hattori T, et al. Effect of operative field irrigation on intraoperative bacterial contamination and postoperative endophthalmitis rates in 25-gauge vitrectomy. Retina 2010; 30:1242–1249.
  17. Zhu Y, Chen X, Chen P, et al. The occurrence rate of acute-onset postoperative endophthalmitis after cataract surgery in Chinese small- and medium- scale departments of ophthalmology. Sci Rep 2017; 7:40776.
  18. Berkelman RL, Holland BW, Anderson RL. Increased bactericidal activity of dilute preparations of povidone-iodine solutions. J Clin Microbiol 1982; 15:635–639.
  19. Hosseini H, Ashraf MJ, Saleh M, et al. Effect of povidone-iodine concentration and exposure time on bacteria isolated from endophthalmitis cases. J Cataract Refract Surg 2012; 38:92–96.
  20. Silas MR, Schroeder RM, Thomson RB, Myers WG. Optimizing the antisepsis protocol: effectiveness of 3 povidone-iodine 1.0% applications versus a single application.
  21. Koerner, J.C.; George, M.J.; Meyer, D.R.; Rosco, M.G.; Habib, M.M. Povidone iodine concentration and dosing in cataract surgery. Ophthalmol. 2018,63,862–868.
  22. Reibaldi, M.; Avitabile, T.; Bandello, F.; Longo, A.; Bonfiglio, V.; Russo, A.; et al. The Effectiveness of 0.6% Povidone Iodine Eye Drops in Reducing the Conjunctival Bacterial Load and Needle Contamination in Patients Undergoing Anti-VEGF Intravitreal Injection: A Prospective, Randomized Study. Clin. Med.2019, 8, 1031.
  23. Musumeci, R.; Bandello, F.; Martinelli, M.; Calaresu, E.; Cocuzza, C.E. In vitro bactericidal activity of 0.6% povidone-iodine eye drops formulation. J. Ophthalmol. 2018,7,1120672118802541.
  24. Pinna, A.; Donadu, M.G.; Usai, D.; D'amicoRicci, G.; Boscia, F.; Zanetti, S. In Vitro antimicrobial activity of a new ophthalmic solution containing povidone-iodine 0.6% (IODIM®).2018,96,111.
  25. Friedman DA, Mason JO 3rd, Emond T, McGwin G Jr. Povidone-iodine contact time and lid speculum use during intravitreal injection. Retina 2013; 33:975–981.
  26. Nakashizuka, H.; Shoji, J.; Shimada, H.; Yuzawa, M. Experimental Visualization and Quantification of Vitreous Contamination Following Intravitreal Injections. Retina2016,36,1882–1887.
  27. Jiang J, Wu M, Shen T. The toxic effect of different concentrations of povidone iodine on the rabbit's cornea. Cutan Ocul Toxicol 2009; 28:119–124.
  28. ElKitkat RS, Ebeid WM, Habib EK, Shoukry Y. Safety of intracameral injection of minimal bactericidal concentration of povidone iodine on the corneal endothelium in a rabbit model. Cornea 2016; 35:72–76.
  29. Jiang J, Wu M, Shen T. The toxic effect of different concentrations of povidone iodine on the rabbit's cornea. Cutan Ocul Toxicol 2009; 28:119–124.
  30. Chabrolle JP, Rossier A. Goitre and hypothyroidism in the newborn after cutaneous absorption of iodine. Arch Dis Child 1978; 53:495–498.
  31. Oakley CL, Vote BJ. Aqueous chlorhexidine is an effective alternative to povidone-iodine for intravitreal injection prophylaxis. Acta Ophthalmol[Internet] 2017 [Epub ahead of print]; Available from: http://dx.doi.org/10.1111/aos.13340.
  32. Hsu HY, Lind JT, Tseng L, Miller D. Ocular flora and their antibiotic resistance patterns in the Midwest: a prospective study of patients undergoing cataract surgery. Am J Ophthalmol 2013; 155:36–44e2.
  33. Grzybowski A, Brona P, Kim SJ. Microbial flora and resistance in ophthalmology: a review. Graefes Arch Clin Exp Ophthalmol 2017; 255:851–862.
  34. Kim SJ, Toma HS. Antimicrobial resistance and ophthalmic antibiotics: 1-year results of a longitudinal controlled study of patients undergoing intravitreal injections. Arch Ophthalmol 2011; 129:1180–1188.
  35. Hsu J, Gerstenblith AT, Garg SJ, Vander JF. Conjunctival flora antibiotic resistance patterns after serial intravitreal injections without post injection topical antibiotics. Am J Ophthalmol 2014; 157:514–580.
  36. Mazoteras P, Quiles MG, Martins Bispo PJ, et al. Analysis of intraocular lens biofilms and fluids after long-term uncomplicated cataract surgery. Am J Ophthalmol 2016; 169:46–57.
  37. Speaker MG, Menikoff JA. Prophylaxis of endophthalmitis with topical povidone- iodine. Ophthalmology 1991; 98:1769–1775.
  38. Schwartz SG, Flynn HW Jr, Grzybowski A, et al. Intracameral antibiotics and cataract surgery: endophthalmitis rates, costs, and stewardship. Ophthalmology 2016; 123:1411–1413.
  39. Wu P-C, Li M, Chang S-J, et al. Risk of endophthalmitis after cataract surgery using different protocols for povidone- iodine preoperative disinfection. J Ocul Pharmacol Ther 2006; 22:54–61.
  40. Halachmi-Eyal O, Halachimi-Eyal O, Lang Y, et al. Preoperative topical moxifloxacin 0.5% and povidone-iodine 5. 0% versus povidone-iodine 5 0% alone to reduce bacterial colonization in the conjunctival sac J Cataract Refract Surg 2009; 35:2109–2114.
  41. Eslami, Jamshid Ph.D; Rezaei, Roghayeh M.Sc; Jamali, Hossein M.D; Sedaghat, Ahad M.D; Nowroozzadeh, M. Hossein M.D Effect of topical povidone-iodine 10% plus levofloxacin 0.5% one hour before cataract surgery in eliminating perioperative conjunctival flora, Journal of Cataract & Refractive Surgery: September 16, 2020.
  42. Grzybowski A. The role of antibiotics in the prevention of postintravitreal anti- VEGF endophthalmitis: primum non nocere! Eye. Eye (Lond) 2014; 28:500.
  43. Schwartz SG, Flynn HW, Grzybowski A. Controversies in topical antibiotics use with intravitreal injections. Curr Pharm Des 2015; 21:4703–4706.
  44. Modjtahedi BS, van Zyl T, Pandya HK, et al. Endophthalmitis after intravitreal injections in patients with self-reported iodine allergy. Am J Ophthalmol 2016; 170:68–74.
  45. Cheung CSY, Wong AWT, Lui A, et al. Incidence of endophthalmitis and use of antibiotic prophylaxis after intravitreal injections. Ophthalmology 2012; 119:1609–1614.
  46. Shimada H, Nakashizuka H, Hattori T, et al. Prophylaxis for acute scleral buckle infection using 0.25% povidone-iodine ocular surface irrigation during surgery. Int Ophthalmol 2014; 34:211–216.
  47. Lindquist TD, Maxwell AJ, Miller TD, et al. Preparation of corneal donor eyes comparing 1% versus 5% povidone-iodine. Cornea 2011; 30: 333–337.
  48. Nishida H, Risemberg HM. Silver nitrate ophthalmic solution and chemical conjunctivities. Pediatrics 1975; 56:368–373.
  49. Isenberg SJ, Apt L, Yoshimori R, et al. Povidone-iodine for ophthalmia neonatorum prophylaxis. Am J Ophthalmol 1994; 118:701–706.
  50. Isenberg SJ, Apt L, Wood M. A controlled trial of povidone-iodine as prophylaxis against ophthalmia neonatorum. N Engl J Med 1995; 332:562–566.
  51. Khan FA, Hussain MA, Khan Niazi SP, et al. Efficacy of 2.5% and 1.25% povidone-iodine solution for prophylaxis of ophthalmia neonatorum. J Coll Physicians Surg Pak 2016; 26:121–124.
  52. Isenberg SJ, Apt L, Valenton M, et al. Prospective, randomized clinical trial of povidone-iodine 1.25% solution versus topical antibiotics for treatment of bacterial keratitis. Am J Ophthalmol [Internet] 2016; 176:244–253; Available from: http://dx.doi.org/10.1016/j.ajo.2016.10.004
  53. Sauerbrei A, Sehr K, Eichhorn U, et al. Inactivation of human adenovirus genome by different groups of disinfectants. J Hosp Infect 2004;57:67–72.
  54. Sauerbrei A, Eichhorn U, Scheibenzuber M, et al. Hexon denaturation of human adenoviruses by different groups of biocides. J Hosp Infect 2007;65:264–70.
  55. Shorter E, Whiteside M, Harthan J, et al. Safety and tolerability of a one-time, in-office administration of 5% povidone-iodine in the treatment of adenoviral conjunctivitis: The Reducing Adenoviral Patient Infected Days (RAPID) study. Ocul Surf 2019;17:828–32.
  56. Trinavarat A, Atchaneeyasakul L-O. Treatment of epidemic keratoconjunctivitis with 2% povidone-iodine: a pilot study. J Ocul Pharmacol Ther 2012;28:53–8.
  57. Yazar H, Yarbag A, Balci M, et al. The effects of povidone iodine (pH 4.2) on patients with adenoviral conjunctivitis. J Pak Med Assoc 2016;66:968–70.
  58. Özen Tunay Z, Ozdemir O, Petricli IS. Povidone iodine in the treatment of adenoviral conjunctivitis in infants. Cutan Ocul Toxicol 2015;34:12–15.
  59. Pepose JS, Narvekar A, Liu W, et al. A randomized controlled trial of povidone-iodine/dexamethasone ophthalmic suspension for acute viral conjunctivitis. Clin Ophthalmol 2019;13:535–44
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.